GW-501516 for sale

GW-501516 is a PPAR agonist (peroxisome proliferator-activated receptor), originally developed for hyperlipidemia, obesity, metabolic dysfunction, and cardiac disease by GlaxoSmithKline, a multinational pharmaceutical company.

The compound is known also by other names Endoburol, Cardarine, and is often used in research studies, cited as a PPARδ agonist.

Various studies have shown GW-501516 to impact fatty acid metabolism, skeletal muscle endurance, and glucose/insulin balance.

As PPARδ plays an important role in mitochondrial respiration, temperature regulation, inflammation mediation, skin and muscle repair, skeletal reprogramming, and keratinocyte differentiation, it can be assumed that GW501516 may have an impact on these additional areas. https://academic.oup.com/endo/article/151/4/1560/2456696?login=true

One mouse study clearly demonstrates the impact of GW5015016 in endurance levels of mice, both in trained and untrained mouse subjects.

After three weeks of GW-501516, trained rats demonstrated a 31.2 percent increase in their total running distance, whereas untrained rats increased their total distance by 68.6 percent. Even one week of GW5015016 increased the running distance by 48.6 percent over the control group.

Of the group that both received Cardarine and were previously trained to run, higher usage of longer saturated fatty acids, as well as triglycerides, were shown to enhance running endurance, likely due to increased fatty acid metabolism after PPARδ activation which up-regulates PDK4 and other mediating pathways of fatty acid oxidation. (https://www.nature.com/articles/srep09884?post=06172017a)

Molecular analyses revealed that PPARδ is involved in exercise-induced reprogramming of muscle fibers and skeletal muscle metabolism by regulating the expression of genes associated with contractile proteins, mitochondrial biogenesis, and lipid oxidation.

Another study confirmed the above by administering GW501516 to mice who were fed a high-fat diet. The dosed group experienced only a slight weight loss but metabolic markers such as decreased insulin resistance, increased metabolic rate, increased mitochondria, and reduced lipids in skeletal muscle were noted. Additionally, glucose in plasma and insulin in blood was decreased in genetically obese mice.